Paula J. Malone, PhD, is Founder and President of Wings Foundation, Inc. She is a retired developmental/clinical psychologist, who first worked in hospital and clinic settings developing and running programs for families and children, neonates to adolescents. In private clinical practice, Dr. Malone developed a multi-disciplinary practice, Comprehensive Psychological Services, LLC, to serve the mental health of children, families and adults throughout Delaware and portions of Pennsylvania and New Jersey. She became involved with The Wellness Community Delaware (now Cancer Support Community Delaware), volunteering and ultimately becoming a Board Member. In 2004, Dr. Malone joined the National Board of The Wellness Community (now Cancer Support Community). In 2010, Dr. Malone and the Wings Foundation made a leadership gift to Cancer Support Community’s Research and Training Institute (RTI). Dr. Malone’s interest in supporting CSC, its affiliates and the RTI, stems not only from her previous professional involvement with cancer patients, but from personal issues as well: she has survived longer, cancer-free, than any other female for generations on both sides of her family and has been a caregiver to two who passed away. She has three children and six grandchildren. Dr. Malone is a licensed pilot and a certified scuba diver.

John brings 16 years of Life Sciences Commercial Strategy to Deloitte Consulting, having served most of the world’s largest life sciences clients in the areas of value, access, pricing, commercial and launch strategy. He is focused on bringing solutions to the growing challenge of sustainable pricing, affordability, access, and value capture for within the biopharmaceutical arena – having served >100 unique products from small molecules to cell/gene therapies. 

Prior to joining Deloitte, John led DRG Consulting’s US Pricing and Market Access Practice, which was a commercial strategy consultancy focused on US pricing, reimbursement, and market access. John partners with the life sciences industry to develop innovative solutions focused on optimizing patient access, improving customer engagement, and finding new ways to create and translate value in the market. 

Outside of professional duties, John has presented at multiple leading industry conferences regarding biosimilar commercial strategy and better incorporating value into benefit structures. John has served as an adjunct professor for the University of Sciences MBA program and is a regular guest lecturer for the Rutgers MBA program. In addition,  John currently serves on the National Board of Directors for the Cancer Support Community. In May 2019, John was named the PM360 Elite Mentor Award winner by PM360 Magazine. 

John completed an MPA in Public Health at the University of Delaware and holds a BA in Public Administration from Shippensburg University. 

Jill Durovsik is the Past Board Chair of the Cancer Support Community, a global nonprofit network of 175 locations which deliver $50 million in free support to cancer patients and their families annually. Jill has a long and varied history with the organization, having been a founding member of the Philadelphia affiliate over 25 years ago and more recently was the Founding Chair of the organization’s Research and Training Institute, dedicated to conducting cutting edge psychosocial behavioral and survivorship research. Prior to CSC, Jill spent the bulk of her career in financial services and building entrepreneurial companies. Ms. Durovsik currently serves on the Women’s Board of PAFA. She is also a Board Member of Vetri Community Partnership. She is a graduate of Skidmore College from which she received the “Creative Thought Matters Award of Distinction” in 2016. Ms. Durovsik lives in Philadelphia with her husband Tom.

Björn is a senior partner in our Paris office. He works with pharmaceutical and biotech companies, health systems, payors and providers on cancer-related topics. He leads the McKinsey Cancer Center globally and is also a leader in our Life Sciences Practice in France. With a PhD and post-doctoral training in molecular oncology, he is a respected peer of both senior executives and research scientists.

Björn’s work covers the whole value chain from early discovery strategies through clinical development to commercialization and reimbursement for cancer medicines. In addition, he supports health systems leaders and manufacturers in defining “adequate outcome” approaches to cancer treatment and developing innovative collaborations to serve patients’ needs.

Recent examples of his work include:

• Leading an 18-month programme involving multiple health systems globally to improve care and outcomes in colorectal cancer
• Helping a client to design the clinical trials for its oncology therapy
• Supporting a number of biotech and pharmaceutical companies in developing go-to-market strategies
• Advising on local, regional and global launch readiness programmes for primary care and specialty care drugs
• Working with a number of pharmaceutical companies to achieve a comprehensive transformation of their R&D function

Outside his client work, Björn leads McKinsey's Cancer Congress Series of satellite meetings at major global professional conferences such as the American Society for Clinical Oncology.

Before joining the London office, Björn worked in our Berlin and New Jersey offices. He continues to serve clients in Europe, the United States, Japan and throughout the world.

Dylan H. Roby, PhD, is Associate Chair and Associate Professor in the Department of Health Policy and Management at the University of Maryland School of Public Health. His research focus is on Medicaid, community health centers, safety net hospitals, delivery system change, and the Affordable Care Act's implications for insurance markets, system redesign and access to care. He teaches courses on health politics and policy in the MHA, MPH and PhD programs in the department. Roby collaborates with colleagues at UC Berkeley and UCLA on the California Simulation of Insurance Markets (CalSIM) microsimulation model (www.calsim.org), which he helped develop over the past decade, and is a member of the cost analysis team for the California Health Benefit Review Program (www.chbrp.org). Although his primary academic appointment is in the University of Maryland's School of Public Health, he is a faculty associate with the UCLA Center for Health Policy Research and an adjunct associate professor of health policy and management at UCLA. Dr. Roby has been interviewed and quoted by various media outlets, including the Los Angeles Times, New York Times, CNN, Fox News, Al Jazeera America, Cosmopolitan, CBS radio, and NPR-affiliates including KPCC, WAMU, Wisconsin Public Radio, and KQED.

As the former director (2012-2014) of the Health Economics and Evaluation Research Program at the UCLA Center for Health Policy Research, Dr. Roby helped developed the Center's capacity for analysis of Medicaid claims data, Medicaid waiver evaluation, and conducting confidential data analyses and surveys. He served as the associate director of the UCLA MPH Program in Health Policy and Management from 2010-2012. Prior to becoming the director of Health Economics and Evaluation Research, he was a senior researcher at the Center from 2003 to 2011. Prior to that, Dr. Roby worked for four years as a senior research associate at The George Washington University Center for Health Services Research and Policy. He worked on safety net issues, including data analysis and research on community health centers and public hospitals. During his first stint in Washington, DC, he also worked for the National Association of Community Health Centers, the National Governors' Association's Center for Best Practices, and the Progressive Policy Institute. Prior to that, he was a research assistant at the UCLA Center for Health Policy Research.

Roby graduated from UCLA with a bachelor's degree in geography and a minor in public policy. He earned his doctoral degree in public policy from The George Washington University.

Michael is global co-head of the Office of Government Affairs. He joined Goldman Sachs as a managing director in 2009.

Prior to joining the firm, Michael was executive vice president for Global Advocacy at the Securities Industry and Financial Markets Association (SIFMA), where he was responsible for global legal, governmental, and legislative affairs and advocacy initiatives. Previously, he was Deputy Staff Director of the US House Financial Services Committee and he also had joint responsibility for Committee policy related to the banking, securities and insurance industries.

Earlier in his career, Michael worked at Mercantile Bankshares Corporation, where he held several senior positions, including executive vice president and chief administrative officer. Before joining Mercantile, he held the position of Senior Minority Counsel with the House Financial Services Committee. Michael has also held positions at JPMorgan Chase & Co. and was an associate at Davis Polk & Wardwell with the financial institutions practice.

Michael earned a BA from Notre Dame and a JD from Notre Dame Law School.

Sharyl Nass, Ph.D. is Director of the Board on Health Care Services and Director of the National Cancer Policy Forum at the National Academies of Sciences, Engineering, and Medicine. The Board’s activities pertain to the organization, financing, effectiveness, workforce, and delivery of health care. The Cancer Forum examines policy issues pertaining to the entire continuum of cancer research and care. For more than 15 years, Dr. Nass has worked on a broad range of health policy topics that includes the quality and safety of care, clinical trials, oversight of health research, developing biomarkers and omics-based tests to guide patient care, technologies and quality standards for breast imaging, strategies for large-scale biomedical science, and contraceptive research and development. With a Ph.D. in cell and tumor biology from Georgetown University and postdoctoral training at the Johns Hopkins University School of Medicine, she has published papers on the cell and molecular biology of breast cancer. She also holds a BS in genetics and an MS in Endocrinology/Reproductive Physiology, both from the University of Wisconsin-Madison. In addition, she studied developmental genetics and molecular biology at the Max Planck Institute in Germany under a fellowship from the Heinrich Hertz-Stiftung Foundation. She was the 2007 recipient of the Cecil Award for Excellence in Health Policy Research, the 2010 recipient of a Distinguished Service Award from the National Academies, and the 2012 recipient of the Institute of Medicine staff team achievement award (as the team leader).